Form 4: Vigil Neuroscience CEO Disposes Shares in Sanofi Merger

Vigil Neuroscience CEO Ivana Magovcevic-Liebisch disposed of all her common stock and stock options as part of the company's acquisition by Sanofi, effective August 5, 2025.

Summary

• Ivana Magovcevic-Liebisch, President and CEO, and Director of Vigil Neuroscience, Inc., reported the disposition of all her common stock and stock options.
• The disposition occurred on August 5, 2025, as a result of the merger between Vigil Neuroscience, Inc. and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Sanofi.
• At the effective time of the merger, each share of Vigil Neuroscience Common Stock was converted into the right to receive $8.00 per share in cash (the "Closing Amount") plus one Contingent Value Right (CVR).
• The CVR represents the right to receive an additional $2.00 payable in cash, conditioned upon the satisfaction of a certain clinical milestone, bringing the total potential merger consideration to $10.00 per share.
• All outstanding unvested stock options were accelerated and became fully vested at the effective time.
• Stock options with an exercise price less than the $8.00 Closing Amount were cancelled and converted into a cash payment equal to the product of the number of shares subject to the option multiplied by the excess of the Closing Amount over the exercise price, plus one CVR per share.
• Stock options with an exercise price equal to or greater than $8.00 but less than $10.00 were cancelled and converted into one CVR per share, with a potential cash payment if the milestone is achieved equal to $10.00 minus the exercise price.
• Following these transactions, Ivana Magovcevic-Liebisch beneficially owns 0 shares of common stock and 0 derivative securities of Vigil Neuroscience, Inc.

Sentiment

Score: 7

Explanation: The acquisition by Sanofi provides a clear exit strategy and liquidity for shareholders, with a guaranteed cash component and potential upside from a contingent value right. This is generally positive for shareholders of the acquired company, though it marks the end of its independent public trading.

Positives

• The acquisition by Sanofi provides a clear exit strategy and liquidity for Vigil Neuroscience shareholders.
• Shareholders receive a guaranteed cash component of $8.00 per share at closing, plus potential upside from a Contingent Value Right (CVR) of $2.00 per share.
• All unvested stock options held by insiders were accelerated and fully vested, benefiting option holders by converting their equity into merger consideration.

Negatives

• Vigil Neuroscience, Inc. ceases to be an independent publicly traded entity, meaning shareholders lose direct exposure to its future independent growth.
• The full $10.00 per share consideration is contingent on a clinical milestone, introducing uncertainty regarding the realization of the $2.00 CVR portion.

Risks

• The Contingent Value Right (CVR) payment of $2.00 per share is contingent upon the satisfaction of a specific clinical milestone, and therefore, its receipt is not guaranteed.

Future Outlook

Vigil Neuroscience will operate as a wholly-owned subsidiary of Sanofi, with its strategic direction and operations integrated into Sanofi's broader pharmaceutical and biotechnology portfolio. The future realization of the CVR payment is dependent on the achievement of a specific clinical milestone.

Industry Context

This merger reflects a common trend in the biotechnology and pharmaceutical sectors where larger companies acquire smaller, innovative firms to bolster their drug pipelines, intellectual property, and market presence. Sanofi's acquisition of Vigil Neuroscience aligns with the industry's strategic focus on expanding therapeutic areas through targeted M&A activities.

Comparison to Industry Standards

• This Form 4 reports an insider's disposition of shares due to a merger, rather than operational or financial performance. Therefore, direct comparisons to industry-standard financial results or project outcomes are not applicable.
• The terms of the merger, including the premium paid and the structure of the contingent value right, would typically be evaluated against comparable M&A transactions in the biotech sector, but this filing does not provide sufficient detail for such an assessment.

Stakeholder Impact

• Shareholders: Receive cash and Contingent Value Rights for their shares, effectively exiting their direct equity position in Vigil Neuroscience.
• Employees: Vigil Neuroscience employees will become part of Sanofi, which may involve integration processes and potential changes in roles or organizational structure.
• Customers/Partners: Future business relationships will be conducted with Sanofi, potentially leading to new opportunities or adjustments in existing agreements.

Next Steps

• Integration of Vigil Neuroscience's operations and assets into Sanofi's corporate structure.
• Monitoring for the achievement of the clinical milestone that triggers the Contingent Value Right (CVR) payment.

Key Dates

Recommendation

The company has been acquired by Sanofi, and its shares are being converted into cash and contingent value rights. There is no longer an independent public market for Vigil Neuroscience shares. Therefore, existing shareholders are effectively selling their shares as part of the merger, and new investors cannot acquire shares in the independent entity.

Keywords

Vigil Neuroscience, Sanofi, Merger, Acquisition, Form 4, Insider Transaction, Biotechnology, Pharmaceuticals, CVR, Contingent Value Right, Stock Options